Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9475	Companies
185452	Keywords
117801	Articles
99309	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 08/21/2025 at 15:05, 3 months 14 days ago

Jaguar Health Targets Global Expansion for Canalevia®

FDA Approval Jaguar Health Canalevia Dog Diarrhea Treatment Animal Health Summit
PRESS RELEASE

published on 08/21/2025 at 15:00, 3 months 14 days ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit

FDA Approval Canalevia-CA1 Partnerships Animal Health Diarrhea Treatment
BRIEF

published on 08/19/2025 at 22:20, 3 months 16 days ago

Jaguar Health Announces Approval of All Proposals at Annual Meeting

Crofelemer FDA Approval Jaguar Health Annual Meeting Partnership Strategy
PRESS RELEASE

published on 08/19/2025 at 22:15, 3 months 16 days ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte to provide updates on crofelemer trial results and regulatory pathway at Emerging Growth Conference. Annual meeting results and company strategy also discussed

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference Regulatory Pathway
BRIEF

published on 08/19/2025 at 15:05, 3 months 16 days ago

Jaguar Health's Napo Pharmaceuticals Seeks FDA Guidance on Crofelemer for Rare Pediatric Disease

Napo Pharmaceuticals Jaguar Health Crofelemer Trials FDA Meeting MVID Treatment
PRESS RELEASE

published on 08/19/2025 at 15:00, 3 months 16 days ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting
BRIEF

published on 08/14/2025 at 14:05, 3 months 21 days ago

Jaguar Health's Q2 2025 Financial Growth and Future Plans

Jaguar Health Financial Strategy Q2 2025 Revenue Mytesi Growth Crofelemer Research
PRESS RELEASE

published on 08/14/2025 at 14:00, 3 months 21 days ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue
Jaguar Health, Inc. reports 35% revenue increase in Q2 2025 for prescription & non-prescription products, including license revenue. Mytesi prescription volume up 6.5%. Crofelemer trial yields positive results

Jaguar Health Inc. FDA Meeting Crofelemer Trial Q2 2025 Revenue Mytesi Prescription Volume
BRIEF

published on 08/12/2025 at 15:05, 3 months 23 days ago

Jaguar Health Announces Investor Webcast on August 14, 2025

Financial Results Pharmaceuticals Investor Webcast Jaguar Health Lisa Conte
PRESS RELEASE

published on 08/12/2025 at 15:00, 3 months 23 days ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates
Jaguar Health, Inc. to conduct investor webcast on August 14, 2025 to review Q2 financials and corporate updates. CEO Lisa Conte presenting at Emerging Growth Conference on August 20, 2025

Investor Webcast Lisa Conte Emerging Growth Conference Jaguar Health Inc. Q2 Financials

Accesswire

Published on 12/05/2025 at 02:35, 11 hours 1 minute ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 11 hours 6 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 36 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 31 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 36 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 36 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 36 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 31 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 36 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 36 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 51 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 36 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 51 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 52 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE